 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...1920212223242526272829...266267» |
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Tumor mutational burden: SWOG S1616: Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma (clinicaltrials.gov) - Feb 15, 2024
P2, N=94, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Aug 2023 --> Dec 2024 | Trial primary completion date: Mar 2022 --> Sep 2023
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date: NRG-GY003: Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Feb 15, 2024
P2, N=100, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Aug 2023 --> Dec 2024 | Trial primary completion date: Mar 2022 --> Sep 2023 Trial completion date: Dec 2023 --> Dec 2024
- | KRAS-EphA-2-CAR-DC / Chinese PLA General Hospital
Enrollment change, Combination therapy, IO biomarker, Metastases: CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - Feb 15, 2024
P1, N=15, Recruiting, Sponsor: Chinese PLA General Hospital
Trial completion date: Dec 2023 --> Dec 2024 N=10 --> 15
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Trial completion date, Trial primary completion date: TDM for Optimized Outcome in Patients With mRCC. (clinicaltrials.gov) - Feb 15, 2024
P=N/A, N=200, Recruiting, Sponsor: Aarhus University Hospital
N=10 --> 15 N=400 --> 200 | Trial completion date: Nov 2023 --> May 2027 | Trial primary completion date: Dec 2022 --> Nov 2026
- | Skyclarys (omaveloxolone) / Biogen
Phase classification: RTA 408 Capsules in Patients With Melanoma - REVEAL (clinicaltrials.gov) - Feb 15, 2024
P1/2, N=41, Completed, Sponsor: Reata, a wholly owned subsidiary of Biogen
N=400 --> 200 | Trial completion date: Nov 2023 --> May 2027 | Trial primary completion date: Dec 2022 --> Nov 2026 Phase classification: P1b/2 --> P1/2
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, Checkpoint inhibition: Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients (clinicaltrials.gov) - Feb 15, 2024
P2, N=60, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||| BMS-986253 / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed: CA027-002: A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers (clinicaltrials.gov) - Feb 13, 2024
P1/2, N=372, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Phase classification: P1b/2 --> P1/2 Recruiting --> Active, not recruiting
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion: CheckMate 7C9: A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India (clinicaltrials.gov) - Feb 13, 2024
P4, N=101, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Monotherapy: CheckMate 914: A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney (clinicaltrials.gov) - Feb 13, 2024
P3, N=1653, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS, ciforadenant (CPI-444) / Corvus Pharma
Enrollment closed, Phase classification, Enrollment change: Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. (clinicaltrials.gov) - Feb 13, 2024
P1/2, N=24, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1/2 | N=15 --> 24
- || izuralimab (XmAb23104) / Xencor
Enrollment closed, Metastases: A Study of XmAb (clinicaltrials.gov) - Feb 12, 2024
P1, N=300, Active, not recruiting, Sponsor: Xencor, Inc.
Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1/2 | N=15 --> 24 Recruiting --> Active, not recruiting
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: Discussion to: Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer. (Pubmed Central) - Feb 10, 2024
Recruiting --> Active, not recruiting No abstract available
- || Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Review, Journal, Combination therapy, Checkpoint inhibition: Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: a case report and review of the literature. (Pubmed Central) - Feb 10, 2024
No abstract available In addition to previously reported risk factors, immune checkpoint inhibitor combination therapy can exacerbate nephrotic syndrome compared to immune checkpoint inhibitor monotherapy.
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: The Effect of Non-Overlapping Somatic Mutations in BRAF, NRAS, NF1, or CKIT on the Incidence and Outcome of Brain Metastases during Immune Checkpoint Inhibitor Therapy of Metastatic Melanoma. (Pubmed Central) - Feb 10, 2024
Next-gen molecular sequencing of tumors in metastatic melanoma patients was useful in identifying genetic subpopulations with an increased or reduced risk of brain metastases. This may allow eventual personalization of screening strategies.
- | everolimus / Generic mfg.
Journal, Checkpoint inhibition: Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival. (Pubmed Central) - Feb 10, 2024
This may allow eventual personalization of screening strategies. This novel approach to investigating survival has allowed us to conduct all indirect head-to-head comparisons between these agents in a context where no "real" comparative trials have been conducted.
- ||| Leukine (sargramostim) / Partner Therap
Review, Journal, Adverse events, Checkpoint inhibition: Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for Cancer. (Pubmed Central) - Feb 10, 2024
In a prospective, randomized study (ECOG 1608), advanced melanoma patients had a reduction in grade 3-5 GI irAEs and less frequent colonic perforation in the sargramostim plus ipilimumab arm compared to ipilimumab alone. Sargramostim continues to be studied with ICIs for the prophylactic management of irAEs while also potentially providing a survival benefit.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Preoperative immune checkpoint inhibition and cryoablation in early-stage breast cancer. (Pubmed Central) - Feb 9, 2024
Sargramostim continues to be studied with ICIs for the prophylactic management of irAEs while also potentially providing a survival benefit. After dual ICB and before cryoablation, T
- | Opdivo (nivolumab) / Ono Pharma, BMS, Rituxan (rituximab) / Roche, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition: Mononeuritis multiplex following immune checkpoint inhibitors in malignant pleural mesothelioma. (Pubmed Central) - Feb 9, 2024
We report the occurrence of mononeuritis multiplex, a very rare adverse event of immune checkpoint inhibitors, in the three patients with mesothelioma. Clinicians must be aware of this severe, yet treatable adverse event.
- | relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, PD(L)-1 Biomarker, IO biomarker: Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma. (Pubmed Central) - Feb 8, 2024
After pCSI with concurrent nivolumab, the addition of relatlimab, and BRAF-targeted therapy, he remained alive 7 months after LMD diagnosis despite central nervous system progression...He received pCSI with concurrent ipilimumab and nivolumab, then nivolumab maintenance...Adding an ICI to pCSI is feasible for patients with LMD and demonstrates a tolerable toxicity profile. While prospective evaluation is ultimately warranted, pCSI with ICI may confer survival benefits, even after prior ICI.
- || Clinical, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Checkpoint block, Immuno-oncology: Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1? and interleukin-6: biochemical implications in cardio-immuno-oncology. (Pubmed Central) - Feb 7, 2024
levels were also increased by PDL-1/CTLA-4 and PD-1/LAG-3 combined blocking agents compared to untreated cells and monotherapies. Data of the present study, although in vitro, indicate that combinatorial immune checkpoint blockade, induce a pro- inflammatory phenotype, thus indicating that these therapies should be closely monitored by the multidisciplinary team consisting of oncologists, cardiologists and immunologists.
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Phase classification: ICON: Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast Cancer (clinicaltrials.gov) - Feb 7, 2024
P2, N=82, Completed, Sponsor: Oslo University Hospital
Data of the present study, although in vitro, indicate that combinatorial immune checkpoint blockade, induce a pro- inflammatory phenotype, thus indicating that these therapies should be closely monitored by the multidisciplinary team consisting of oncologists, cardiologists and immunologists. Active, not recruiting --> Completed | Phase classification: P2b --> P2
- ||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy (clinicaltrials.gov) - Feb 7, 2024
P2, N=20, Active, not recruiting, Sponsor: Dan Zandberg
Active, not recruiting --> Completed | Phase classification: P2b --> P2 Recruiting --> Active, not recruiting | N=40 --> 20 | Trial completion date: Aug 2029 --> Aug 2024 | Trial primary completion date: Aug 2029 --> Aug 2023
- Detection of drug-induced interstitial lung disease caused by cancer treatment using electronic nose exhaled breath analysis (Congress Hall Foyer) - Feb 6, 2024 - Abstract #ELCC2024ELCC_580;
Recruiting --> Active, not recruiting | N=40 --> 20 | Trial completion date: Aug 2029 --> Aug 2024 | Trial primary completion date: Aug 2029 --> Aug 2023 Table: 246P Baseline Case n=20 Control n=20 Female 9 (45) 9 (45) Age 65.25
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Circulating cytokines levels as predictive biomarkers in pleural mesothelioma: Preliminary data from a prospective translational study (Congress Hall Foyer) - Feb 6, 2024 - Abstract #ELCC2024ELCC_501;
Conclusions In this series, circulating cytokines were differently expressed in E vs NE pts; some cytokines showed a prognostic and predictive role after ChT or ICIs. ICIs may have a key role in decreasing some cytokines levels.
- Libtayo (cemiplimab-rwlc) / Regeneron, Yervoy (ipilimumab) / Ono Pharma, BMS
Patient-reported outcomes (PROs) of cemiplimab (CEMI) + platinum doublet chemotherapy (CHEMO) + ipilimumab (IPI) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-lung 3 part 1 (Congress Hall Foyer) - Feb 6, 2024 - Abstract #ELCC2024ELCC_400;
P3
Conclusions In patients with PD-L1 <50% aNSCLC, CEMI+IPI+CHEMO vs CHEMO resulted in significant overall improvement and delayed TTD in multiple cancer-related and lung cancer-specific PROs. Positive PROs further support the favourable benefit
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Treatment-free survival (TFS) in patients (pts) with mNSCLC treated with 1L nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone (4 cycles) in CheckMate (CM) 9LA (Congress Hall Foyer) - Feb 6, 2024 - Abstract #ELCC2024ELCC_399;
P3
Conclusions In this CM 9LA analysis, 1L NIVO + IPI + chemo demonstrated an improvement in TFS with and without toxicity, regardless of tumor PD-L1 expression level, over 48 mo compared with chemo. These data reflect durable clinical benefit of NIVO + IPI + chemo following tx cessation.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Combination therapy, Checkpoint inhibition, Metastases: Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinoma. (Pubmed Central) - Feb 6, 2024
These data reflect durable clinical benefit of NIVO + IPI + chemo following tx cessation. From our analysis of real-world data, a better outcome of PFS was expected in the ICI-TKI group compared with that in the ICI-ICI group, while there was no significant difference in OS or ORR.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Combination therapy, Metastases: A Case of Pathological Complete Response for MSI-High Locally Advanced Unresectable Transverse Colon Cancer Treated with Nivolumab plus Ipilimumab Combination Therapy (Pubmed Central) - Feb 6, 2024
After 4 courses of combination therapy, she was judged to be in partial response and surgery was performed. Histopathological diagnosis of the surgical specimen showed complete response, and she is still alive without recurrence 15 months after surgery.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Surgery, Metastases: A Case of Locally Advanced Unresectable Esophageal Cancer Treated with Nivolumab and Ipilimumab Therapy Followed by Surgery (Pubmed Central) - Feb 6, 2024
The resected specimen revealed that fewer than 50% of malignant cells remained viable and residual cancer cells were noticeably absent, particularly in the enlarged lymph nodes. We herein present the details of this case and discuss the literature concerning surgery following immune checkpoint inhibitor therapy.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: Unresectable Esophageal Cancer on the Elderly Woman Which Was Treated Effectively with Ipilimumab plus Nivolumab-A Case Report (Pubmed Central) - Feb 6, 2024
Until now, the standard treatment regimen was cisplatin plus 5-FU as the chemotherapy for unresectable advanced esophageal cancer...The patient's condition of the disease was improved temporarily after change chemotherapy to paclitaxel as the second-line therapy, but she died due to disease progression at 11.4 months from initiation of treatment. Ipilimumab plus nivolumab can become one of the effective treatments for patients who are impossible to treat with conventional chemotherapy.
- | Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma. (Pubmed Central) - Feb 6, 2024
Ipilimumab plus nivolumab can become one of the effective treatments for patients who are impossible to treat with conventional chemotherapy. Archival blood and/or tumor tissue samples were collected from 361 patients with advanced-stage ipilimumab-treated (
- || Yervoy (ipilimumab) / Ono Pharma, BMS
Review, Journal: Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers. (Pubmed Central) - Feb 6, 2024
The approval of ipilimumab and the development of similar pharmacological agents targeting cell surface proteins on Treg cells demonstrates that such intervention may overcome resistance in cancer patients...These new small molecule inhibitors often target specific intracellular signaling pathways [e.g., phosphoinositide-3-kinase delta (PI3K-?)] that play an important role in regulating the function of Treg cells. This review will summarize the lessons currently applied to develop novel clinical agents that target Treg cells.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Tumor mutational burden: Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer (clinicaltrials.gov) - Feb 6, 2024
P1, N=21, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
This review will summarize the lessons currently applied to develop novel clinical agents that target Treg cells. Recruiting --> Active, not recruiting
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed: Surgical Nivolumab And Ipilimumab For Recurrent GBM (clinicaltrials.gov) - Feb 6, 2024
P1, N=63, Active, not recruiting, Sponsor: Patrick Wen, MD
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: A chronic non-healing ulcer plantar. (Pubmed Central) - Feb 5, 2024
Instead of surgery, we decided to start with immunotherapy consisting of Ipilimumab and Nivolumab. A complete response could be achieved without surgery of any tumors, including the primary melanoma.
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Journal, Checkpoint inhibition: Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series. (Pubmed Central) - Feb 5, 2024
Management is heterogeneous. CNIs appear most likely to result in toxicity resolution in the shortest time period, however, are associated with poorer oncological outcomes in contrast to vedolizumab.
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Retrospective data, Journal, PD(L)-1 Biomarker, IO biomarker: Volumetric growth rate of incidentally found meningiomas on immunotherapy. (Pubmed Central) - Feb 5, 2024
Check-point inhibitors may impact the natural history of meningiomas. Additional research is needed to define potential clinical indications and treatment goals.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy. (Pubmed Central) - Feb 5, 2024
Environmental factors that are associated with particular seasons may contribute to the development of certain irAEs and suggest the potential effect of environmental triggers. The identification of these factors may enhance preventive and therapeutic strategies to reduce the morbidity of irAEs.
- || Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Biomarker, Clinical data, Journal, Monotherapy, Real-world evidence, PD(L)-1 Biomarker, IO biomarker, Real-world, Metastases: PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma. (Pubmed Central) - Feb 5, 2024
The identification of these factors may enhance preventive and therapeutic strategies to reduce the morbidity of irAEs. Our findings support previous exploratory analyses of Checkmate-067, highlighting that improved clinical outcomes with combination therapy are not established in unselected patients with high (?1%) tumor PD-L1 expression.
- || Journal, Checkpoint inhibition, Adverse drug reaction: Assessment of Neurologic Safety Profile of Immune Checkpoint Inhibitors: Evaluation of Adverse Drug Reaction Reports. (Pubmed Central) - Feb 4, 2024
These findings suggest the consideration of a revision of the neurologic safety profile of ICIs. Furthermore, the necessity for additional ad-hoc research is emphasized.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1/2 trial: MARIANE: Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma (clinicaltrials.gov) - Feb 2, 2024
P1/2, N=80, Not yet recruiting, Sponsor: The Netherlands Cancer Institute
- || Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Analysis of Clinical Success and Molecular Mechanisms of Action of Novel Anti-glioblastoma Drugs: A Review. (Pubmed Central) - Feb 1, 2024
Combining anti-GBM drugs appears to be a key direction for increasing treatment effectiveness and overall survival. Radiotherapy of GBM can increase the effect of combination drug therapy.
- || Retrospective data, Review, Journal, Metastases: Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data. (Pubmed Central) - Jan 30, 2024
The treatment ranking analysis of the entire cohort showed that nivolumab?+?cabozantinib (81%) had the highest likelihood of improving OS, followed by nivolumab?+?ipilimumab (75%); pembrolizumab?+?lenvatinib had the highest likelihood of improving PFS (99%), ORR (97%), and CR (86%)...Further, OS benefits of ICI doublets were not inferior to those of ICI?+?tyrosine kinase inhibitor combinations. Recommendation of combination therapies with ICIs and/or tyrosine kinase inhibitors based on survival benefits and patient pretreatment risk classification will help advance personalized medicine for mRCC.
- || Clinical, Journal: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease. (Pubmed Central) - Jan 29, 2024
Further studies on the safety of more potent dual immune checkpoint therapy are needed. We conclude that immunotherapy should not categorically be withheld from patients with AILD.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Sutent (sunitinib) / Pfizer, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, HEOR, Metastases: The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214. (Pubmed Central) - Jan 28, 2024
P3
We conclude that immunotherapy should not categorically be withheld from patients with AILD. In aRCC, patient-reported outcomes are important for HRQoL and prognostic evaluation.
- | Jemperli (dostarlimab-gxly) / GSK, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: Cross-trial comparisons for the adjuvant treatment of MSI colorectal cancer: dare to dream the future scenarios. (Pubmed Central) - Jan 27, 2024
The future implications of these findings will depend on how the data mature over time. In this manuscript, we attempt to explore the potential scenarios that may unfold in the near future.
- | Opdivo (nivolumab) / Ono Pharma, BMS, DUET-101 / Scopus, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, PD(L)-1 Biomarker, IO biomarker: Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy. (Pubmed Central) - Jan 27, 2024
To better understand immune alterations associated with ICB resistance, we assessed blood biomarkers in renal cancer patients classified as responders or non-responders to first line nivolumab/ipilimumab immunotherapy...To assess whether STAT3 inhibition within these cell subsets can promote antitumor immune responses and/or enhance sensitivity to ICB in vivo, we used an original antisense oligonucleotide (ASO) strategy for myeloid-cell selective STAT3 knockdown (CpG-STAT3ASO)...Therapeutic efficacy correlated with activation of dendritic cells (DCs) and M1 macrophages in the tumor microenvironment, reduced percentages of regulatory T cells (Tregs) and the expansion of CD8 T cells in both tumor models. Our study underscores the potential of using myeloid-cell targeted CpG-STAT3 inhibitors for genitourinary cancer therapy to disrupt tolerogenic signaling, restore immune cell activity and sensitivity to immune checkpoint inhibitors and/or T cell-based immunotherapies.
- ||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
P3 data, Journal, PD(L)-1 Biomarker, IO biomarker: Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial. (Pubmed Central) - Jan 26, 2024
High CNV burden may contribute to the cold immune microenvironment. Soluble inflammation/immune-related proteins in the blood have the potential to monitor therapeutic benefit from ICI treatment in SqNSCLC patients.
- ||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Retrospective data, Journal, Adverse events: Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use. (Pubmed Central) - Jan 26, 2024
Our study demonstrated that multisystem irAEs are prevalent amongst patients receiving ipilimumab and nivolumab. It is important for both physician education and the counseling and consent of patients to monitor the potential for multiple irAEs.
- Remicade (infliximab) / J&J, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
OF BROKEN MUSCLES AND BROKEN HEARTS: ICI-MEDIATED FATAL MYOSITIS AND MYOCARDITIS (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_7488;
Myocarditis may occur concurrently with myositis or myasthenia gravis in approximately 30% patients. The risk of developing myocarditis was higher among patients receiving combination anti-PD-1 based therapies.